Investors in Catapult Group International (ASX:CAT) have seen incredible returns of 656% over the past three years

We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. One such superstar is Catapult Group International Ltd (ASX:CAT), which saw its share price soar 656% in three years. Also pleasing for shareholders was the 63% gain in the last three months. We love happy stories like this one. The company should be really proud of that performance!
So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Catapult Group International isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
Over the last three years Catapult Group International has grown its revenue at 14% annually. That's pretty nice growth. Some shareholders might think that the share price rise of 96% per year is a lucky result, considering the level of revenue growth. A hot stock like this is usually well worth taking a closer look at, as long as you don't let the fear of missing out (FOMO) impact your thinking.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
We're pleased to report that Catapult Group International shareholders have received a total shareholder return of 203% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 38% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Catapult Group International , and understanding them should be part of your investment process.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

19 minutes ago

• Yahoo

Here's Why Globant S.A. (GLOB) Has Trembled More Than 55% This Year

Globant S.A. (NYSE:GLOB) is one of the 11 Best Tech Stocks to Buy On the Dip. The company released its Q1 2025 results on May 15. Globant S.A. (NYSE:GLOB) missed revenue and EPS estimates causing the stock to dip. It posted a revenue of $611.09 million, reflecting 7% growth. However, this was below the market consensus by $10.37 million. The EPS of $1.50 also missed estimates by $0.08. On May 16, Arvind Ramnani analyst at Piper Sandler downgraded Globant S.A. (NYSE:GLOB) from Buy to Hold, while also adjusting the price target from $154 to $116. The analyst noted they had already estimated the macro headwinds, which impacted the revenue growth thereby reducing its estimates. A close-up of an experienced game engineer's hands typing a complex code on a laptop. Impax US Sustainable Economy Fund mentioned Globant S.A. (NYSE:GLOB) in its Q1 2025 investor letter. The fund noted that the company delivered satisfactory results driven by broad demand through various industry verticals and also witnessed revenue growth in new markets. Despite the satisfactory growth, the stock has trembled more than 55.87% on a year-to-date basis mainly due to a complex macroeconomic environment impacting customer spending. The fund anticipates the economic pressure to impact the revenue projections. Management of Globant S.A. (NYSE:GLOB) anticipates second-quarter revenue to be at least $612.0 million, reflecting 4.2% year-over-year growth. Impax US Sustainable Economy Fund stated the following regarding Globant S.A. (NYSE:GLOB) in its Q1 2025 investor letter: 'Globant S.A. (NYSE:GLOB) (Information Technology) is a software solutions provider helping to enhance productivity and drive increasing digital infrastructure in the transition to a more sustainable economy. The stock was down despite delivering satisfactory results, due to broad demand across multiple industry verticals and significant revenue growth in new markets. However, political volatility and macroeconomic pressures in Latin America are expected to affect demand, resulting in slightly lower revenue projections for the upcoming fiscal year.' While we acknowledge the potential of GLOB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

Yahoo

19 minutes ago

• Yahoo

Roth Capital Hikes Verona Pharma's (VRNA) Price Target to $116 On COPD Market Prospects

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating. The adjustment follows remarks by Dr Frank Sciurba, who discussed unmet chronic obstructive pulmonary disease needs. A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections. The doctor shared positive insights on the company's product Ohtuvayre, highlighting its complementary role in newly approved biologics. According to Roth Capital, the enhanced understanding of Verona Pharma's Ohtuvayre's distinctive efficacy and risk profile is already sparking greater interest among investors. Consequently, the research firm raised its price target in response to the increased attention and appreciation of Verona Pharma's offering. The research firm remains bullish about the company's growth potential. Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. It focuses on developing treatments for chronic obstructive pulmonary disease (COPD). They are known for their product, ensifentrine, an investigational, inhaled, small molecule that acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), combining bronchodilator and anti-inflammatory properties. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio

Wall Street Journal

37 minutes ago

• Wall Street Journal

The Tax Bill Would Deliver a Big Win for Private Schools—and Investors

Republicans' tax-and-spending megabill would give the school-choice movement a major, long-sought victory—and deliver an unusually generous tax break to wealthy taxpayers. The bill includes a new way for taxpayers—whether they are parents or not—to direct tax dollars to private-school scholarships instead of the Treasury. There is an extra twist: It could deliver virtually risk-free profits to some savvy investors.